Literature DB >> 29382659

Prognostic Value of the Acute-to-Chronic Glycemic Ratio at Admission in Acute Myocardial Infarction: A Prospective Study.

Giancarlo Marenzi1, Nicola Cosentino2, Valentina Milazzo2, Monica De Metrio2, Milena Cecere2, Susanna Mosca2, Mara Rubino2, Jeness Campodonico2, Marco Moltrasio2, Ivana Marana2, Marco Grazi2, Gianfranco Lauri2, Alice Bonomi2, Fabrizio Veglia2, Roberto Manfrini2, Antonio L Bartorelli2,3.   

Abstract

OBJECTIVE: Acute hyperglycemia is a powerful predictor of poor prognosis in acute myocardial infarction (AMI), particularly in patients without diabetes. This emphasizes the importance of an acute glycemic rise rather than glycemia level at admission alone. We investigated in AMI whether the combined evaluation of acute and chronic glycemic levels, as compared with admission glycemia alone, may have a better prognostic value. RESEARCH DESIGN AND METHODS: We prospectively measured admission glycemia and estimated average chronic glucose levels (mg/dL) by the following formula: [(28.7 × glycosylated hemoglobin %) - 46.7], and calculated the acute-to-chronic (A/C) glycemic ratio in 1,553 consecutive AMI patients (mean ± SD age 67 ± 13 years). The primary end point was the combination of in-hospital mortality, acute pulmonary edema, and cardiogenic shock.
RESULTS: The primary end point rate increased in parallel with A/C glycemic ratio tertiles (5%, 8%, and 20%, respectively; P for trend <0.0001). A parallel increase was observed in troponin I peak value (15 ± 34 ng/mL, 34 ± 66 ng/mL, and 68 ± 131 ng/mL; P < 0.0001). At multivariable analysis, A/C glycemic ratio remained an independent predictor of the primary end point and of troponin I peak value, even after adjustment for major confounders. At reclassification analyses, A/C glycemic ratio showed the best prognostic power in predicting the primary end point as compared with glycemia at admission in the entire population (net reclassification improvement 12% [95% CI 4-20]; P = 0.003) and, particularly, in patients with diabetes (27% [95% CI 14-40]; P < 0.0001).
CONCLUSIONS: In AMI patients with diabetes, A/C glycemic ratio is a better predictor of in-hospital morbidity and mortality than glycemia at admission.
© 2018 by the American Diabetes Association.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29382659     DOI: 10.2337/dc17-1732

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  16 in total

1.  Short and long-term prognosis of admission hyperglycemia in patients with and without diabetes after acute myocardial infarction: a retrospective cohort study.

Authors:  Hanzohra Upur; Jia-Li Li; Xiao-Guang Zou; Yu-Ying Hu; He-Yin Yang; Alimujiang Abudoureyimu; Anwar Abliz; Mamatili Abdukerim; Min Huang
Journal:  Cardiovasc Diabetol       Date:  2022-06-23       Impact factor: 8.949

2.  Association of stress hyperglycemia ratio and in-hospital mortality in patients with coronary artery disease: insights from a large cohort study.

Authors:  Wei Xu; Qirui Song; Xiang Wang; Zinan Zhao; Xuyang Meng; Chenxi Xia; Yibo Xie; Chenguang Yang; Ying Guo; Yatong Zhang; Fang Wang
Journal:  Cardiovasc Diabetol       Date:  2022-10-19       Impact factor: 8.949

Review 3.  Stress Induced Hyperglycemia in the Context of Acute Coronary Syndrome: Definitions, Interventions, and Underlying Mechanisms.

Authors:  Mingmin Li; Guo Chen; Yingqing Feng; Xuyu He
Journal:  Front Cardiovasc Med       Date:  2021-05-12

4.  Association between Admission Hyperglycemia and Culprit Lesion Characteristics in Nondiabetic Patients with Acute Myocardial Infarction: An Intravascular Optical Coherence Tomography Study.

Authors:  Jinying Zhou; Zhaoxue Sheng; Chen Liu; Peng Zhou; Jiannan Li; Runzhen Chen; Li Song; Hanjun Zhao; Hongbing Yan
Journal:  J Diabetes Res       Date:  2020-06-20       Impact factor: 4.011

5.  Augmented glycaemic gap is a marker for an increased risk of post-infarct left ventricular systolic dysfunction.

Authors:  Yong Zhu; Kesen Liu; Shuai Meng; Ruofei Jia; Xuan Lei; Maolin Chen; Kaiyuan Zou; Huagang Zhu; Zening Jin
Journal:  Cardiovasc Diabetol       Date:  2020-07-04       Impact factor: 9.951

6.  The stress hyperglycaemia ratio is associated with left ventricular remodelling after first acute ST-segment elevation myocardial infarction.

Authors:  Shuai Meng; Yong Zhu; Kesen Liu; Ruofei Jia; Jing Nan; Maolin Chen; Xuan Lei; Kaiyuan Zou; Zening Jin
Journal:  BMC Cardiovasc Disord       Date:  2021-02-04       Impact factor: 2.298

7.  Predictive value of stress hyperglycemia ratio for the occurrence of acute kidney injury in acute myocardial infarction patients with diabetes.

Authors:  Side Gao; Qingbo Liu; Hui Chen; Mengyue Yu; Hongwei Li
Journal:  BMC Cardiovasc Disord       Date:  2021-03-30       Impact factor: 2.298

8.  Prognostic impact of admission high-sensitivity C-reactive protein in acute myocardial infarction patients with and without diabetes mellitus.

Authors:  Claudia Lucci; Nicola Cosentino; Stefano Genovese; Jeness Campodonico; Valentina Milazzo; Monica De Metrio; Maurizio Rondinelli; Daniela Riggio; Maria Luisa Biondi; Mara Rubino; Katia Celentano; Alice Bonomi; Nicolò Capra; Fabrizio Veglia; Piergiuseppe Agostoni; Antonio L Bartorelli; Giancarlo Marenzi
Journal:  Cardiovasc Diabetol       Date:  2020-10-20       Impact factor: 9.951

9.  Association of stress hyperglycemia ratio with intracoronary thrombus burden in diabetic patients with ST-segment elevation myocardial infarction.

Authors:  Jiapeng Chu; Jiani Tang; Yan Lai; Yanhua Gao; Zi Ye; Chunyu Guan; Keke Ding; Yian Yao; Fei Chen; Xuebo Liu
Journal:  J Thorac Dis       Date:  2020-11       Impact factor: 3.005

10.  Admission hyperglycemia as an independent predictor of long-term prognosis in acute myocardial infarction patients without diabetes: A retrospective study.

Authors:  Cai-Yan Cui; Ming-Gang Zhou; Lian-Chao Cheng; Tao Ye; Yu-Mei Zhang; Feng Zhu; Si-Yi Li; Xing-Lin Jiang; Qiang Chen; Ling-Yao Qi; Xu Chen; Si-Qi Yang; Lin Cai
Journal:  J Diabetes Investig       Date:  2020-12-28       Impact factor: 4.232

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.